

Risiken erkennen – Gesundheit schützen

Einladung zum 74. ZEBET-Seminar

A long shelf-life in vitro cell model of the human airway epithelium (Mucilair[™]) for inhalation toxicity assessment

Dr. Song Huang and Dr. Samuel Constant Epithelix Sàrl Geneva, Switzerland http://www.epithelix.com

Most of the *in vitro* cell models for long term testing of chemicals suffer of at least two shortcomings: 1. The failure of reproducing the *in vivo* physiological characteristics of the corresponding tissues, such is the case for the immortalized cell lines. 2. A limited shelf-life, for example, the freshly established primary cell cultures. Our company, Epithelix, has developed and is commercializing a novel *in vitro* cell model of the human airway epithelium (MucilAir[™]) which is free of these limitations.

MucilAirTM is morphologically and functionally differentiated and it can also be maintained at a homeostatic state for more than one year. The typical ultra-structures of the human airway epithelium, such as the tight junctions, the cilia, the basal cells, the mucous cells can be observed. The epithelium is electrically tight (TEER $\approx 450 \ \Omega.cm^2$). The ion channels are fully functional and respond normally to their specific inhibitors and activators. Moreover, the epithelial cells react to pro-inflammatory mediators in a physiological manner. Remarkably, the epithelium has a strong capacity of regeneration after mechanical or chemical injuries. Epithelia from several different pathologies can be reconstructed (e.g. Asthma, COPD, CF, smoker, etc.).

Due to its unique long shelf-life of one year and cultured at air-liquid interface, this model is used for studying the human respiratory diseases, and for testing the longterm/chronic effects of drugs/chemicals on respiratory tract. Several applications of MucilAir[™] relevant to inhalation toxicity assessment will be presented.

TERMIN: Mittwoch, 16. Dezember 2009, <u>14:00 Uhr</u>

ORT: Bundesinstitut für Risikobewertung (BfR) Bereich Berlin-Marienfelde <u>Haus 3, Großer Sitzungssaal D 146</u> Diedersdorfer Weg 1, 12277 Berlin <u>http://www.bfr.bund.de/cd/5409</u>

KONTAKT: Bundesinstitut für Risikobewertung (BfR) FG 92 – ZEBET - Alternativmethoden zu Tierversuchen Dr. Lena Smirnova Diedersdorfer Weg 1, 12277 Berlin-Marienfelde Tel.: 030-18412-2266 Fax: 030-18412-2958 E-Mail: lena.smirnova@bfr.bund.de